Stoke Therapeutics(STOK) Drops 1.21% Despite Biogen Partnership

Stoke Therapeutics(STOK) shares fell 1.21% today, reaching their highest level since February 2025, with an intraday gain of 0.30%.

Marshall Wace LLP, a significant institutional investor, reduced its stake in Stoke Therapeutics by 43.1% during the fourth quarter. This substantial decrease in holdings could negatively impact market sentiment and potentially influence the stock price.

In February, Biogen announced a collaboration with Stoke Therapeutics to develop and commercialize zorevunersen. This partnership can boost investor confidence and potentially increase future revenue, positively affecting the company's stock price.

Stoke Therapeutics has a short interest of 12.09 million shares, representing 25.73% of the float. High short interest can lead to volatility in the stock price, as it indicates a significant portion of traders are betting against the stock.